Intraperitoneal chemotherapy

Critical Reviews in Oncology/Hematology

Volumn 31, Issue 3, 1999, Pages 239-246

  Markman, Maurie ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; PACLITAXEL;

CHEMOTHERAPY; DIGESTIVE SYSTEM CANCER; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MESOTHELIOMA; OVARY CANCER; REVIEW; TUMOR VOLUME;

EID: 0032833725     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00017-7     Document Type: Article

References (44)

1. Weisberger A.S., Levine B., Storaasli J.P. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J. Am. Med. Assoc. 159:1955;1704-1707.
2. Dedrick R.L., Myers C.E., Bungay P.M. et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62:1978;1-9.
3. Dedrick R.L. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin. Oncol. 12(3;Suppl 4):1985;1-6.
4. Alberts D.S., Young L., Mason N. et al. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin. Oncol. 12(3;Suppl 4):1985;38-42.
5. Markman M. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Crit. Rev. Oncol./Hematol. 14:1993;15-28.
6. Howell S.B., Pfeifle C.E., Wung W.E. et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97:1982;845-851.
7. Casper E.S., Kelsen D.P., Alcock N.W. et al. Ip cisplatin in patients with malignant ascites: pharmacokinetics evaluation and comparison with the iv route. Cancer. Treat. Rep. 67:1983;325-338.
8. Lopez J.A., Krikorian J.G., Reich S.D. et al. Clinical pharmacology of intraperitoneal cisplatin. Gynecol. Oncol. 20:1985;1-9.
9. Pretorius R.G., Hacker N.F., Berek J.S. et al. Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat. Rep. 67:1983;1085-1092.
10. Markman M., Rowinsky E., Hakes T. et al. Phase 1 trial of intraperitoneal taxol: a Gynecologic Oncology Group Study. J. Clin. Oncol. 10:1992;1485-1491.
11. Francis P., Rowinsky E., Schneider J. et al. Phase 1 feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J. Clin. Oncol. 13:1995;2961-2967.
12. Markman M., Reichman B., Hakes T. et al. Responses to second- line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J. Clin. Oncol. 9:1991;1801-1805.
13. Markman M., Berek J.S., Blessing J.A. et al. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based IP chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of IP cisplatin and recombinant alpha-interferon. Gynecol. Oncol. 45:1992;3-8.
14. Markman M., Blessing J.A., Major F. et al. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group Study. Gynecol. Oncol. 50:1993;191-195.
15. Markman M., Brady M.F., Spirtos N.M. et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J. Clin. Oncol. 16:1998;2620-2624.
16. Berek J.S., Hacker N.F., Lichtenstein A. et al. Intraperitoneal recombinant alpha-interferon for 'salvage' immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer Res. 45:1985;4447-4453.
17. West G.W., Weichselbau R., Little J.B. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res. 40:1980;3665-3668.
18. Durand R.E. Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res. 41:1981;3495-3498.
19. Ozols R.F., Locker G.Y., Doroshow J.H. et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 39:1979;3209-3214.
20. Nederman T., Carlsson J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother. Pharmacol. 13:1984;131-135.
21. Los G., Mutsaers P.H.A., van der Vijgh W.J.F. et al. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 49:1989;3380-3384.
22. Howell S.B., Zimm S., Markman M. et al. Long term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J. Clin. Oncol. 5:1987;1607-1612.
23. Markman M., Reichman B., Hakes T. et al. Impact on survival of surgically-defined favorable responses to salvage intraperitoneal chemotherapy in small volume residual ovarian cancer. J. Clin. Oncol. 10:1992;1479-1484.
24. Piver M.S., Recio F.O., Baker T.R. et al. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer. Cancer. 73:1994;1693-1698.
25. Alberts D.S., Liu P.Y., Hannigan E.V. et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl. J. Med. 335:1996;1950-1955.
26. McGuire W.P., Hoskins W.J., Brady M.F. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl. J. Med. 334:1996;1-6.
27. Markman M., Bundy B., Benda J. et al. Randomized phase 3 study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatin (CARB) followed by IV PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer (OC): an Intergroup Trial (GOG, SWOG, ECOG) (abstract 1392). Proc. Am. Soc. Clin. Oncol. 17:1998;361.
28. Shapiro F., Schneider J., Markman M. et al. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Gynecol. Oncol. 67:1997;39-45.
29. Rubin S.C., Hoskins W.J., Saigo P.E. et al. Recurrence following negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am. J. Obstet. Gynecol. 159:1988;1094-1098.
30. Barakat R.R., Almadrones L., Venkatraman E.S. et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol. Oncol. 69:1998;17-22.
31. Markman M. Intraperitoneal therapy of ovarian cancer. Semin. Oncol. 25:1998;356-360.
32. Los G., Verdegaal E.M.E., Mutsaers P.H.A. et al. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother. Pharmacol. 28:1991;159-165.
33. Markman M., Reichman B., Hakes T. et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small volume residual ovarian cancer. Gynecol. Oncol. 50:1993;100-104.
34. Pfeifle C.E., Howell S.B., Markman M. Intracavitary cisplatin chemotherapy for mesothelioma. Cancer Treat. Rep. 69:1985;205-207.
35. Markman M., Cleary S., Pfeifle C.E. et al. Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer. 58:1986;18-21.
36. Markman M., Kelsen D. Intraperitoneal cisplatin and mitomycin as treatment of malignant peritoneal mesothelioma. Reg. Cancer Treat. 2:1989;49-53.
37. Markman M., Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J. Cancer Res. Clin. Oncol. 118:1992;547-550.
38. Antman K.H., Klegar K.L., Pomfret E.A. et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 2:1985;977-980.
39. Lederman G.S., Recht A., Herman T. et al. Long-term survival in peritoneal mesothelioma: the role of radiotherapy and combined modality treatment. Cancer. 59:1987;1882-1886.
40. Markman M. Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies? Cancer Invest. 13(6):1995;625-628.
41. Sugarbaker P.H., Zhu B.-W., Sese G.B. et al. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis. Colon Rectum. 36:1993;323-329.
42. Kelsen D.P., Saltz L., Cohen A.M. et al. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. Cancer. 74:1994;2224-2233.
43. Hagiwara A., Takahashi T., Kojima O. et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet. 339:1992;629-631.
44. Rosen H.R., Jatzko G., Repse S. et al. Adjuvant intraperitoneal chemotherapy with carbon-absorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J. Clin. Oncol. 16:1998;2733-2738.